614 McKinley Place N.E.
389 articles about Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) today announced William A. Geist has been appointed President, Protein Sciences Segment, effective January 3 , 2022.
Bio-Techne Corporation today announced it has entered into an option agreement with Wilson Wolf Corporation.
Bio-Techne Corporation (NASDAQ: TECH) today announced the publication of an important manuscript in the journal Scientific Reports, a Nature Research journal, showing proof-of-concept of its proprietary lateral flow technology.
Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at two upcoming investor conferences.
Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel , Executive Vice President and Chief Financial Officer, will present at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021 at 10:00 a.m. EDT .
Bio-Techne Corporation announced that Asuragen, Inc., a Bio-Techne brand, has launched a new kit to detect pathogenic variants in the CFTR gene.
Bio-Techne Corporation (NASDAQ: TECH) today announced that Jim Hippel , Executive Vice President and Chief Financial Officer, will present virtually at the Credit Suisse 30th Annual Healthcare Conference on Tuesday, November 9, 2021 at 11:20 a.m. EST
Bio-Techne Corporation announced the commercial availability of GMP-grade materials manufactured at its St. Paul, MN GMP manufacturing facility.
Bio-Techne Corporation reported its financial results for the first quarter ended September 30, 2021.
Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended September 30, 2021.
Bio-Techne Announces ExoDx Prostate Test Data Publication in the Journal of Prostate Cancer and Prostatic Diseases
Bio-Techne Corporation today announced that Exosome Diagnostics, a Bio-Techne brand, has published important clinical research in the journal Prostate Cancer and Prostatic Diseases , entitled Predicting high-grade prostate cancer at initial biopsy
Bio-Techne To Host Conference Call On November 2, 2021 To Announce First Quarter 2022 Financial Results
Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Tuesday, November 2, 2021 , at 8:00 a.m. CDT to review first quarter 2022 financial results.
Bio-Techne Corporation Bio-Techne announced the launch of a new medium for the expansion and maintenance of induced pluripotent stem cells for use in both research and translational workflows.
Bio-Techne, a leading supplier of high-quality and innovative tools for life science research, therapeutic manufacturing and clinical diagnostics and Carterra Inc., the world leader in high-throughput antibody screening and characterization, announced a clinical research collaboration studying COVID-19 variants.
Bio-Techne Corporation announced that Chuck Kummeth, President and Chief Executive Officer, will present at the 2021 Virtual Wells Fargo Healthcare Conference on Thursday, September 9, 2021 at 2:00 p.m. EDT.
Bio-Techne Corporation reported its financial results for the fourth quarter ended June 30, 2021.
Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.32 per share for the quarter ended June 30, 2021.
Bio-Techne's RNAscope™ Technology Aids in the Retrospective Tissue Diagnosis of COVID-19 in cases with no previous testing for SARS-CoV-2
Bio-Techne Corporation announced that scientists at the U.S. Centers for Disease Control and Prevention recently highlighted the importance of fixed tissue analysis for retrospective diagnosis of SARS-CoV-2 infection and characterization of viral strains, particularly for fatal cases in which no previous testing for SARS-CoV-2 was performed.
Bio-Techne Corporation announced that management will host its 2021 Investor Day on Friday, September 10, 2021, starting at 9:00 a.m. EDT.
Bio-Techne Corporation and PROGEN announced the launch of the Simple Plex™ Adeno-Associated Virus viral titer assay for AAV2 total capsid quantification.